These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 30419349)

  • 1. DEPDC1, negatively regulated by miR-26b, facilitates cell proliferation via the up-regulation of FOXM1 expression in TNBC.
    Zhang L; Du Y; Xu S; Jiang Y; Yuan C; Zhou L; Ma X; Bai Y; Lu J; Ma J
    Cancer Lett; 2019 Feb; 442():242-251. PubMed ID: 30419349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YTHDC1-dependent m6A modification modulated FOXM1 promotes glycolysis and tumor progression through CENPA in triple-negative breast cancer.
    Shen X; Zhong J; Yu P; Liu F; Peng H; Chen N
    Cancer Sci; 2024 Jun; 115(6):1881-1895. PubMed ID: 38566554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of USP7 induces p53-independent tumor growth suppression in triple-negative breast cancers by destabilizing FOXM1.
    Yi J; Li H; Chu B; Kon N; Hu X; Hu J; Xiong Y; Kaniskan HU; Jin J; Gu W
    Cell Death Differ; 2023 Jul; 30(7):1799-1810. PubMed ID: 37291217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative transcriptome analysis of triple negative breast cancer profiles for identification of druggable targets.
    Arumugam P; Ramesh V; Sampathkumar B; Perumalsamy H; Balusamy SR; Suganya K; Balraj S; Nachimuthu SK; Sundaravadivelu S
    J Biomol Struct Dyn; 2023; 41(21):12106-12119. PubMed ID: 36617953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FOXM1/RNF26/p57 axis regulates the cell cycle to promote the aggressiveness of bladder cancer.
    Yi L; Wang H; Li W; Ye K; Xiong W; Yu H; Jin X
    Cell Death Dis; 2021 Oct; 12(10):944. PubMed ID: 34650035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retraction: DEPDC1 promotes cell proliferation and suppresses sensitivity to chemotherapy in human hepatocellular carcinoma.
    Biosci Rep; 2024 Jul; 44(7):. PubMed ID: 38994710
    [No Abstract]   [Full Text] [Related]  

  • 7. The pro-metastasis effect of circANKS1B in breast cancer.
    Zeng K; He B; Yang BB; Xu T; Chen X; Xu M; Liu X; Sun H; Pan Y; Wang S
    Mol Cancer; 2018 Nov; 17(1):160. PubMed ID: 30454010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor (AR)/miR-520f-3p/SOX9 signaling is involved in altering hepatocellular carcinoma (HCC) cell sensitivity to the Sorafenib therapy under hypoxia via increasing cancer stem cells phenotype.
    Xiao Y; Sun Y; Liu G; Zhao J; Gao Y; Yeh S; Gong L; Chang C
    Cancer Lett; 2019 Mar; 444():175-187. PubMed ID: 30448543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Landscape of Targeted Therapies in TNBC.
    Vagia E; Mahalingam D; Cristofanilli M
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32276534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge.
    Nedeljković M; Damjanović A
    Cells; 2019 Aug; 8(9):. PubMed ID: 31443516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrasound-Guided Breast Biopsy: Improved Accuracy of 10-G Cable-Free Elite Compared With 14-G CCNB.
    Sheng X; Wang Y; Yang F; Lin Y; Xu S; Yin W; Zhou L; Lu J
    J Surg Res; 2020 Mar; 247():172-179. PubMed ID: 31761441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DEPDC1 drives hepatocellular carcinoma cell proliferation, invasion and angiogenesis by regulating the CCL20/CCR6 signaling pathway.
    Guo W; Li H; Liu H; Ma X; Yang S; Wang Z
    Oncol Rep; 2019 Sep; 42(3):1075-1089. PubMed ID: 31322256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of miR-142-3p promotes intestinal epithelial proliferation and barrier function after ischemia/reperfusion injury by targeting FoxM1.
    Wang Y; Jia Z; Zheng M; Wang P; Gao J; Zhang X; Zhou T; Zu G
    Mol Cell Biochem; 2024 May; ():. PubMed ID: 38819598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DEP domain containing 1 as a biomarker for poor prognosis in lung adenocarcinoma.
    Li C; Zhu X
    Heliyon; 2024 May; 10(9):e30642. PubMed ID: 38765113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis and validation reveal DEPDC1 as a potential diagnostic biomarker associated with tumor immunity in non-small-cell lung cancer.
    Lv M; Li X; Yin Z; Yang H; Zhou B
    PLoS One; 2024; 19(4):e0294227. PubMed ID: 38564630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting DEP domain containing 1 in anaplastic thyroid carcinoma: Implications for stemness regulation and malignant phenotype suppression.
    Zhu C; Ke S; Li Y; Zhang W; Che Y; Zhang R; Huang P; Xu T
    Heliyon; 2024 Mar; 10(5):e27150. PubMed ID: 38449652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNAs as the critical regulators of Forkhead box protein family during gynecological and breast tumor progression and metastasis.
    Taghehchian N; Lotfi M; Zangouei AS; Akhlaghipour I; Moghbeli M
    Eur J Med Res; 2023 Sep; 28(1):330. PubMed ID: 37689738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-Nucleus Transcriptome Profiling of Locally Advanced Cervical Squamous Cell Cancer Identifies Neural-Like Progenitor Program Associated with the Efficacy of Radiotherapy.
    Zhang L; Ma J; Zhou D; Zhou J; Hu B; Ma X; Tang J; Bai Y; Chen H; Jing Y
    Adv Sci (Weinh); 2023 Sep; 10(25):e2300348. PubMed ID: 37424047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA repair pathways in breast cancer: from mechanisms to clinical applications.
    Tufail M
    Breast Cancer Res Treat; 2023 Aug; 200(3):305-321. PubMed ID: 37289340
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.